Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MUKESH G HARISINGHANI

Allopathic & Osteopathic Physicians Radiology Diagnostic Radiology

NPI
1659345361
CMS profile
581034
Location
BOSTON, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$79,042.00

87 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $79,042.00 87

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme Corporation $76,242.00 86
Eli Lilly and Company $2,800.00 1

Page 2 of 2; records 51–87 of 87 matching records. This page contains 37 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MUKESH G HARISINGHANI

NPI 1659345361 · CMS profile ID 581034

Allopathic & Osteopathic Physicians / Radiology / Diagnostic Radiology

BOSTON, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–87 of 87 matching records. This page contains 37 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1659345361?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MUKESH G HARISINGHANI, NPI 1659345361, CMS profile ID 581034. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–87 of 87 matching records. This page contains 37 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659345361?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). MUKESH G HARISINGHANI, NPI 1659345361, CMS profile ID 581034. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–87 of 87 matching records. This page contains 37 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659345361?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
MUKESH G HARISINGHANI, NPI 1659345361, CMS profile ID 581034, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–87 of 87 matching records. This page contains 37 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1659345361?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

87 matching records · $79,042.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 87 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–87 of 87.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme Corporation $380.0007/02/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747760539 CMS
Merck Sharp & Dohme Corporation $1,517.0007/02/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747761147 CMS
Merck Sharp & Dohme Corporation $2,276.0007/02/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747761153 CMS
Merck Sharp & Dohme Corporation $120.0006/18/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747620071 CMS
Merck Sharp & Dohme Corporation $550.0006/18/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747620297 CMS
Merck Sharp & Dohme Corporation $4,775.0006/04/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747760489 CMS
Merck Sharp & Dohme Corporation $5,000.0005/26/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747619407 CMS
Merck Sharp & Dohme Corporation $1,549.0005/21/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747619079 CMS
Merck Sharp & Dohme Corporation $2,400.0005/21/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747619525 CMS
Merck Sharp & Dohme Corporation $120.0004/30/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747618761 CMS
Merck Sharp & Dohme Corporation $385.0004/23/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747618783 CMS
Merck Sharp & Dohme Corporation $385.0004/23/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747618785 CMS
Merck Sharp & Dohme Corporation $527.0004/23/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747618787 CMS
Merck Sharp & Dohme Corporation $1,115.0004/23/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747619291 CMS
Merck Sharp & Dohme Corporation $1,164.0004/17/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747618759 CMS
Merck Sharp & Dohme Corporation $180.0004/17/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747618769 CMS
Merck Sharp & Dohme Corporation $560.0004/09/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747627161 CMS
Merck Sharp & Dohme Corporation $1,465.0003/26/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747615271 CMS
Merck Sharp & Dohme Corporation $480.0003/26/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747627129 CMS
Merck Sharp & Dohme Corporation $1,708.0003/19/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747619493 CMS
Merck Sharp & Dohme Corporation $180.0003/19/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747619495 CMS
Merck Sharp & Dohme Corporation $180.0003/19/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747619497 CMS
Merck Sharp & Dohme Corporation $1,256.0003/13/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747619465 CMS
Merck Sharp & Dohme Corporation $1,440.0002/28/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747627127 CMS
Merck Sharp & Dohme Corporation $90.0002/24/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747614959 CMS
Merck Sharp & Dohme Corporation $160.0002/24/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747615327 CMS
Merck Sharp & Dohme Corporation $285.0002/24/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747615625 CMS
Merck Sharp & Dohme Corporation $60.0002/13/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747618791 CMS
Merck Sharp & Dohme Corporation $991.0002/06/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747618799 CMS
Merck Sharp & Dohme Corporation $1,210.0001/27/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747614801 CMS
Merck Sharp & Dohme Corporation $420.0001/23/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747615001 CMS
Merck Sharp & Dohme Corporation $60.0001/23/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747615005 CMS
Merck Sharp & Dohme Corporation $1,032.0001/23/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747615019 CMS
Merck Sharp & Dohme Corporation $800.0001/23/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747627139 CMS
Merck Sharp & Dohme Corporation $1,048.0001/09/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747615021 CMS
Merck Sharp & Dohme Corporation $120.0001/09/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747615023 CMS
Merck Sharp & Dohme Corporation $400.0001/07/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747626595 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $143,790.00 73
PY2020 $79,042.00 87
PY2021 $90,024.00 88
PY2022 $307,610.00 16
PY2023 $351,233.89 30
PY2024 $384,237.84 27
PY2025 $11,711.06 9

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,600.00 1
PY2025 Principal investigator $184,859.05 33
PY2024 Principal investigator $30,802.01 24
PY2023 Recipient $665.08 1
PY2023 Principal investigator $80,710.40 43
PY2022 Recipient $252.00 1
PY2022 Principal investigator $107,217.45 51
PY2021 Principal investigator $230,459.07 69
PY2020 Principal investigator $114,348.01 53
PY2019 Principal investigator $355,508.90 52

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

34 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,695.00 12/09/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202529670
Principal investigator 1 ABBVIE INC. $65.00 12/09/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202529692
Principal investigator 1 ABBVIE INC. $55.00 11/11/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202523767
Principal investigator 1 ABBVIE INC. $1,420.00 11/11/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202523769
Principal investigator 1 GE HEALTHCARE $80,586.00 10/03/2025 Non-covered Recipient Entity
MASSACHUSETTS GENERAL HOSPITAL
MR Research Study No dispute reported 06/30/2026 1244366643
Principal investigator 1 GE HEALTHCARE $13,140.00 10/03/2025 Non-covered Recipient Entity
MASSACHUSETTS GENERAL HOSPITAL
MR Research Study No dispute reported 06/30/2026 1244366655
Principal investigator 1 ABBVIE INC. $3,270.00 08/26/2025 Non-covered Recipient Entity
MGPO RADIOLOGY ASSOCIATES
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202505767
Principal investigator 1 GE HEALTHCARE $6.73 08/05/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
Odyssey No dispute reported 06/30/2026 1244366161
Principal investigator 1 GE HEALTHCARE $33.51 08/05/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
Odyssey No dispute reported 06/30/2026 1244366165
Principal investigator 1 GE HEALTHCARE $13.46 08/05/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
Odyssey No dispute reported 06/30/2026 1244366169
Principal investigator 1 GE HEALTHCARE $6.73 08/05/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
Odyssey No dispute reported 06/30/2026 1244366173
Principal investigator 1 GUERBET LLC $18.40 08/05/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
ODYSSEY DGD-44-065 No dispute reported 06/30/2026 1241225202
Principal investigator 1 GUERBET LLC $45.82 08/05/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
ODYSSEY DGD-44-065 No dispute reported 06/30/2026 1241225204
Principal investigator 1 ABBVIE INC. $6,345.00 07/29/2025 Non-covered Recipient Entity
MGPO RADIOLOGY ASSOCIATES
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202500362
Principal investigator 1 ABBVIE INC. $4,500.00 06/24/2025 Non-covered Recipient Entity
MGPO RADIOLOGY ASSOCIATES
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202492757
Principal investigator 1 AstraZeneca UK Limited $1,600.00 06/24/2025 Non-covered Recipient Entity
MASSACHUSETTS GENERAL PHYS ORG
a randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer No dispute reported 06/30/2026 1185550377
Principal investigator 1 ABBVIE INC. $5,325.00 05/27/2025 Non-covered Recipient Entity
MGPO RADIOLOGY ASSOCIATES
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202486311
Principal investigator 1 ABBVIE INC. $1,425.00 04/29/2025 Non-covered Recipient Entity
MGPO RADIOLOGY ASSOCIATES
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202479857
Principal investigator 1 ABBVIE INC. $15,090.00 03/27/2025 Non-covered Recipient Entity
MGPO RADIOLOGY ASSOCIATES
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202467095
Principal investigator 1 BeiGene, Ltd. $1,485.00 03/27/2025 Non-covered Recipient Entity
MGPO RADIOLOGY ASSOCIATES
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Patients With Localized Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190323260
Recipient Regeneron Pharmaceuticals, Inc. $1,600.00 03/04/2025 Covered Recipient Physician A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1184118191
Principal investigator 1 ABBVIE INC. $17,550.00 02/25/2025 Non-covered Recipient Entity
MGPO RADIOLOGY ASSOCIATES
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202453868
Principal investigator 1 ABBVIE INC. $11,685.00 02/25/2025 Non-covered Recipient Entity
MGPO RADIOLOGY ASSOCIATES
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202453871
Principal investigator 1 BeiGene, Ltd. $1,010.00 02/25/2025 Non-covered Recipient Entity
MGPO RADIOLOGY ASSOCIATES
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Patients With Localized Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190323246
Principal investigator 1 BeiGene, Ltd. $560.00 02/25/2025 Non-covered Recipient Entity
MGPO RADIOLOGY ASSOCIATES
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Patients With Localized Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190323258
Principal investigator 1 GE HEALTHCARE $31.99 02/05/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
Odyssey No dispute reported 06/30/2026 1244366163
Principal investigator 1 GE HEALTHCARE $31.99 02/05/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
Odyssey No dispute reported 06/30/2026 1244366167
Principal investigator 1 GE HEALTHCARE $31.99 02/05/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
Odyssey No dispute reported 06/30/2026 1244366175
Principal investigator 1 GE HEALTHCARE $31.99 02/05/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
Odyssey No dispute reported 06/30/2026 1244366177
Principal investigator 1 GE HEALTHCARE $6.36 01/08/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
Odyssey No dispute reported 06/30/2026 1244366157
Principal investigator 1 GE HEALTHCARE $12.72 01/08/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
Odyssey No dispute reported 06/30/2026 1244366159
Principal investigator 1 GE HEALTHCARE $6.36 01/08/2025 Covered Recipient Teaching Hospital
Massachusetts General Hospital
Odyssey No dispute reported 06/30/2026 1244366171
Principal investigator 1 ABBVIE INC. $17,295.00 01/07/2025 Non-covered Recipient Entity
MGPO RADIOLOGY ASSOCIATES
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202437127
Principal investigator 1 BeiGene, Ltd. $480.00 01/07/2025 Non-covered Recipient Entity
MGPO RADIOLOGY ASSOCIATES
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Patients With Localized Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190323262